#None #Securities Fraud #Radnor #Legal Rights #Capricor Therapeutics

CAPR Investor Alert from Kessler Topaz Meltzer & Check, LLP

Legal Issues Surrounding Capricor Therapeutics, Inc.

A recent securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) by Kessler Topaz Meltzer & Check, LLP on behalf of investors who acquired Capricor securities between December 17, 2025, and July 26, 2026. This lawsuit sheds light on the alleged deception surrounding the company's business operations, particularly concerning its pivotal product candidates and interactions with regulatory authorities.

Who Should Act?

This legal notification is directed at those investors who suffered losses during the aforementioned timeframe. Potential litigants have until September 28, 2026, to file for lead plaintiff status. By stepping forward, these investors can ensure their voices are heard in the ongoing litigation process. To read the formal complaint, interested parties can visit the law firm’s website or review supplementary content detailing the case.

Nature of the Lawsuit

The core allegations of the lawsuit revolve around Capricor’s failure to adequately disclose critical information about its business and product candidates. Specifically, it claims that the company misrepresented vital details related to its lead product candidate's statistical analysis and compliance with FDA requirements. The complaint outlines that Capricor made changes to its statistical analysis plan without the FDA's prior agreement, exposing itself to substantial risk regarding the approval chances of its Biologics License Application (BLA).

On July 27, 2026, the FDA released briefing documents before its advisory committee meeting, indicating that the adjustments made by Capricor were problematic and not scientifically justified, leading to a precipitous drop in stock value—reported at 64% in one day. Investors are urged to consider their positions and assess whether they would like to take part in the recovery process.

What Can Affected Investors Do?

Investors who experienced financial damage as a result of these misrepresentations have several steps they can consider:
1. File for Lead Plaintiff Status: Ensure your position is recognized by applying before the set deadline.
2. Connect with Legal Counsel: Kessler Topaz Meltzer & Check offers free case evaluations without any upfront costs. Their compensation is contingent upon a successful recovery.
3. Stay Informed: Being aware of the developments in the case can directly impact your investment recovery path. Regularly checking the law firm’s pages or contacting them for updates is advisable.

The Role of a Lead Plaintiff

Investors interested in becoming lead plaintiffs can represent their fellow shareholders in guiding the litigation efforts. This role typically involves making crucial decisions regarding the case’s direction and selecting appropriate legal counsel. However, participation as a lead plaintiff or absence from this role does not alter an investor's potential to benefit from any recovering funds.

Conclusion

Kessler Topaz Meltzer & Check, LLP is committed to ensuring that the rights of CAPR investors are upheld. The law firm has an established track record in securities litigation, indicating its expertise in handling such cases. It represents a significant population of both individual and institutional investors, thereby ensuring a collective approach to legal representation.

If you’ve experienced losses from your investment in Capricor, now is the time to take action. For inquiries or to initiate your case evaluation process, you can contact:
Jonathan Naji, Esq.
Phone: (484) 270-1453
Email: [email protected]
Address: Kessler Topaz Meltzer & Check, LLP, 280 King of Prussia Road, Radnor, PA 19087.
Visit the law firm’s website for more information regarding the case.

Remember, timely action can be crucial for maximizing your potential recovery in this matter.